Trials / Completed
CompletedNCT00102037
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in the United States of America (USA). The purpose of this clinical research trial is to understand how safe and effective Recombinant Activated FVII is for reducing bleeding and blood transfusions in patients undergoing spinal fusion surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eptacog alfa (activated) |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2006-02-01
- Completion
- 2006-02-01
- First posted
- 2005-01-20
- Last updated
- 2017-01-13
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00102037. Inclusion in this directory is not an endorsement.